Lyell Immunopharma: Q2 Earnings Snapshot
/PRNewswire/ -- Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy...
The company gave a presentation regarding its lead therapy to treat solid tumors.
Cash, cash equivalents and marketable securities of $787.0 million as of June 30, 2022 provides funding into 2025 and supports advancement of multiple...
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company...
SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...
Cash, cash equivalents and marketable securities of $898 million as of December 31, 2021 supports advancing multi-modality cell therapy pipelineClinical...
LYL797 is an investigational ROR1 CAR T-cell therapy incorporating novel reprogramming technologies for solid tumors SOUTH SAN FRANCISCO, Calif., March ...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (Nasdaq: LYEL), a T-cell reprogramming company dedicated to the...